O-1269

O-1269_structure.png

Synthetic cannabinoid

O-1269
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	30251-30-0
PubChem	3084161
DrugBank
ChemSpider	2340731
KEGG

O-1269 is a synthetic cannabinoid that was developed in the 1990s by a team led by Raphael Mechoulam at the Hebrew University of Jerusalem. It is a potent agonist of the cannabinoid receptors, specifically the CB1 receptor and CB2 receptor.

Chemical Structure

O-1269 is structurally related to other synthetic cannabinoids such as HU-210 and JWH-018. It features a dibenzopyran ring system with a 1,1-dimethylheptyl side chain, which is a common structural motif in many synthetic cannabinoids.

Pharmacology

O-1269 acts as a potent agonist at both the CB1 and CB2 receptors. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes including pain, appetite, mood, and memory. The activation of these receptors by O-1269 can produce effects similar to those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.

Research and Applications

O-1269 has been used in scientific research to better understand the endocannabinoid system and the role of cannabinoid receptors in various physiological and pathological processes. It has also been studied for its potential therapeutic applications, including pain management, neuroprotection, and anti-inflammatory effects.

Legal Status

The legal status of O-1269 varies by country. In some jurisdictions, it may be classified as a controlled substance due to its structural similarity to other synthetic cannabinoids that are regulated.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• Endocannabinoid system
• Raphael Mechoulam
• HU-210
• JWH-018

References

   This article is a medical stub. You can help WikiMD by expanding it!